$REGN
Regeneron Pharmaceuticals Inc Stock $regn

$regn Overview Financials Valuation SEC Filings Company Website

2015 Q3 Form 10-Q Financial Statement

#000153217615000037 Filed on November 04, 2015

Income Statement

Concept	2015 Q3	2014 Q4	2014 Q3
Revenue	$1.137B	$802.3M	$725.8M
YoY Change	56.72%	31.44%	21.57%
Cost Of Revenue	$67.20M	$59.50M	$33.66M
YoY Change	99.67%	23.7%	19.12%
Gross Profit	$1.070B	$742.9M	$692.1M
YoY Change	54.63%	32.12%	21.69%
Gross Profit Margin	94.09%	92.59%	95.36%
Selling, General & Admin	$210.0M	$175.3M	$144.0M
YoY Change	45.83%	113.53%	47.53%
% of Gross Profit	19.62%	23.6%	20.81%
Research & Development	$425.9M	$351.7M	$337.7M
YoY Change	26.11%	31.18%	50.74%
% of Gross Profit	39.8%	47.34%	48.8%
Depreciation & Amortization	$20.70M	$14.10M	$14.10M
YoY Change	46.81%	24.78%	30.56%
% of Gross Profit	1.93%	1.9%	2.04%
Operating Expenses	$635.9M	$175.3M	$481.7M
YoY Change	32.01%	-49.94%	49.77%
Operating Profit	$392.4M	$215.8M	$188.5M
YoY Change	108.22%	1.75%	-20.41%
Interest Expense	$1.715M	-$6.400M	$9.232M
YoY Change	-81.42%	-45.3%	-21.34%
% of Operating Profit	0.44%	-2.97%	4.9%
Other Income/Expense, Net	$867.0K	$3.000M	-$6.641M
YoY Change	-113.06%	-230.43%	-40.27%
Pretax Income	$393.3M	$189.7M	$181.8M
YoY Change	116.3%	-4.28%	-19.43%
Income Tax	$182.9M	$99.63M	$98.45M
% Of Pretax Income	46.5%	52.51%	54.14%
Net Earnings	$210.4M	$90.10M	$83.38M
YoY Change	152.35%	-6.93%	-41.0%
Net Earnings / Revenue	18.5%	11.23%	11.49%
Basic Earnings Per Share	$2.04	$0.89	$0.83
Diluted Earnings Per Share	$1.82	$0.78	$0.73
COMMON SHARES
Basic Shares Outstanding	103.3M shares		100.8M shares
Diluted Shares Outstanding	115.9M shares		117.4M shares

Balance Sheet

Concept	2015 Q3	2014 Q4	2014 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments	$896.0M	$900.0M	$1.042B
YoY Change	-14.01%	29.68%	134.16%
Cash & Equivalents	$654.6M	$648.7M	$646.6M
Short-Term Investments	$241.0M	$252.0M	$396.0M
Other Short-Term Assets	$182.0M	$159.0M	$139.0M
YoY Change	30.94%	78.65%	-3.47%
Inventory	$190.7M	$128.9M	$120.3M
Prepaid Expenses
Receivables	$1.088B	$739.4M	$673.9M
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$2.676B	$2.085B	$2.201B
YoY Change	21.59%	16.02%	34.66%
LONG-TERM ASSETS
Property, Plant & Equipment	$1.475B	$974.3M	$819.0M
YoY Change	80.12%	84.88%	80.43%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments	$681.0M	$460.0M	$453.0M
YoY Change	50.33%	17.95%	37.27%
Other Assets	$4.583M	$3.034M	$3.416M
YoY Change	34.16%	-43.04%	-22.52%
Total Long-Term Assets	$2.507B	$1.753B	$1.539B
YoY Change	62.93%	51.89%	52.93%
TOTAL ASSETS
Total Short-Term Assets	$2.676B	$2.085B	$2.201B
Total Long-Term Assets	$2.507B	$1.753B	$1.539B
Total Assets	$5.183B	$3.838B	$3.739B
YoY Change	38.6%	30.05%	41.62%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$107.0M	$100.0M	$47.00M
YoY Change	127.66%	61.29%	51.61%
Accrued Expenses	$471.0M	$384.0M	$291.0M
YoY Change	61.86%	103.17%	54.79%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$735.0M	$654.7M	$410.2M
YoY Change	79.18%	119.07%	52.65%
LONG-TERM LIABILITIES
Long-Term Debt	$395.0M	$458.0M	$564.0M
YoY Change	-29.96%	-9.31%	17.26%
Other Long-Term Liabilities	$77.91M	$39.80M	$23.75M
YoY Change	228.08%	251.29%	124.6%
Total Long-Term Liabilities	$77.91M	$39.80M	$23.75M
YoY Change	228.08%	251.29%	124.6%
TOTAL LIABILITIES
Total Short-Term Liabilities	$735.0M	$654.7M	$410.2M
Total Long-Term Liabilities	$77.91M	$39.80M	$23.75M
Total Liabilities	$1.886B	$1.287B	$1.188B
YoY Change	58.81%	28.88%	24.98%
SHAREHOLDERS EQUITY
Retained Earnings	$697.7M	$216.6M	$145.2M
YoY Change	380.49%	-333.72%	-176.63%
Common Stock
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)	$288.8M	$169.5M	$43.85M
YoY Change	558.57%
Treasury Stock Shares	3.437M shares	2.018M shares	521.9K shares
Shareholders Equity	$3.297B	$2.550B	$2.552B
YoY Change
Total Liabilities & Shareholders Equity	$5.183B	$3.838B	$3.739B
YoY Change	38.6%	30.05%	41.62%

Cashflow Statement

Concept	2015 Q3	2014 Q4	2014 Q3
OPERATING ACTIVITIES
Net Income	$210.4M	$90.10M	$83.38M
YoY Change	152.35%	-6.93%	-41.0%
Depreciation, Depletion And Amortization	$20.70M	$14.10M	$14.10M
YoY Change	46.81%	24.78%	30.56%
Cash From Operating Activities	$892.9M	$198.1M	$164.4M
YoY Change	443.13%	-28.41%	77.73%
INVESTING ACTIVITIES
Capital Expenditures	-$146.1M	-$117.5M	-$79.80M
YoY Change	83.08%	70.29%	152.53%
Acquisitions
YoY Change
Other Investing Activities	-$137.0M	$174.2M	-$43.30M
YoY Change	216.4%	-525.92%	-76.31%
Cash From Investing Activities	-$283.2M	$56.60M	-$123.0M
YoY Change	130.24%	-151.45%	-42.63%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	-345.7M	-252.6M	5.200M
YoY Change	-6748.08%	-339.43%	44.44%
NET CHANGE
Cash From Operating Activities	892.9M	198.1M	164.4M
Cash From Investing Activities	-283.2M	56.60M	-123.0M
Cash From Financing Activities	-345.7M	-252.6M	5.200M
Net Change In Cash	264.0M	2.100M	46.60M
YoY Change	466.52%	-99.23%	-139.39%
FREE CASH FLOW
Cash From Operating Activities	$892.9M	$198.1M	$164.4M
Capital Expenditures	-$146.1M	-$117.5M	-$79.80M
Free Cash Flow	$1.039B	$315.6M	$244.2M
YoY Change	325.47%	-8.71%	96.78%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	dei	Amendment Flag AmendmentFlag	false
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q3
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2015
	dei	Document Period End Date DocumentPeriodEndDate	2015-09-30
	dei	Document Type DocumentType	10-Q
	dei	Entity Central Index Key EntityCentralIndexKey	0000872589
	dei	Entity Filer Category EntityFilerCategory	Large Accelerated Filer
	dei	Entity Registrant Name EntityRegistrantName	REGENERON PHARMACEUTICALS INC
CY2013Q4	regn	Accrued Capital Expenditures AccruedCapitalExpenditures	16100000	USD
CY2014Q3	regn	Accrued Capital Expenditures AccruedCapitalExpenditures	38600000	USD
CY2014Q4	regn	Accrued Capital Expenditures AccruedCapitalExpenditures	56200000	USD
CY2015Q3	regn	Accrued Capital Expenditures AccruedCapitalExpenditures	84700000	USD
CY2014Q4	regn	Accrued Clinical Trial Expense Current AccruedClinicalTrialExpenseCurrent	41555000	USD
CY2015Q3	regn	Accrued Clinical Trial Expense Current AccruedClinicalTrialExpenseCurrent	62569000	USD
CY2014Q4	regn	Accruedsalesrelatedchargesdeductionsandroyalties Accruedsalesrelatedchargesdeductionsandroyalties	133085000	USD
CY2015Q3	regn	Accruedsalesrelatedchargesdeductionsandroyalties Accruedsalesrelatedchargesdeductionsandroyalties	160941000	USD
CY2014Q3	regn	Branded Prescription Drug Fee BrandedPrescriptionDrugFee	40600000	USD
CY2014Q3	regn	Costofmanufacturing Costofmanufacturing	21938000	USD
	regn	Costofmanufacturing Costofmanufacturing	54471000	USD
CY2015Q3	regn	Costofmanufacturing Costofmanufacturing	41884000	USD
	regn	Costofmanufacturing Costofmanufacturing	111254000	USD
	regn	Debt Conversion DebtConversion	61100000	USD
	regn	Debt Conversion DebtConversion	146000000	USD
	regn	Decreaseintotalcashfromfinancing Decreaseintotalcashfromfinancing	9400000	USD
CY2014Q4	regn	Deferred Revenue From Related Party Current DeferredRevenueFromRelatedPartyCurrent	15927000	USD
CY2015Q3	regn	Deferred Revenue From Related Party Current DeferredRevenueFromRelatedPartyCurrent	100908000	USD
CY2014Q4	regn	Deferred Revenue From Related Party Noncurrent DeferredRevenueFromRelatedPartyNoncurrent	62819000	USD
CY2015Q3	regn	Deferred Revenue From Related Party Noncurrent DeferredRevenueFromRelatedPartyNoncurrent	599339000	USD
CY2014Q4	regn	Facility Lease Obligations Noncurrent FacilityLeaseObligationsNoncurrent	310938000	USD
CY2015Q3	regn	Facility Lease Obligations Noncurrent FacilityLeaseObligationsNoncurrent	364144000	USD
	regn	Facilityleaseobligationrecognizedduringtheperiod Facilityleaseobligationrecognizedduringtheperiod	92600000	USD
	regn	Facilityleaseobligationrecognizedduringtheperiod Facilityleaseobligationrecognizedduringtheperiod	27000000	USD
	regn	Increaseintotalcashfromoperating Increaseintotalcashfromoperating	9400000	USD
CY2014Q3	regn	Incremental Common Shares Attributable To Nonvested Restricted Shares IncrementalCommonSharesAttributableToNonvestedRestrictedShares	430000	shares
	regn	Incremental Common Shares Attributable To Nonvested Restricted Shares IncrementalCommonSharesAttributableToNonvestedRestrictedShares	413000	shares
CY2015Q3	regn	Incremental Common Shares Attributable To Nonvested Restricted Shares IncrementalCommonSharesAttributableToNonvestedRestrictedShares	481000	shares
	regn	Incremental Common Shares Attributable To Nonvested Restricted Shares IncrementalCommonSharesAttributableToNonvestedRestrictedShares	475000	shares
	regn	Levelsoftwelvemonthsalesatwhichsalesmilestonepaymentswerereceived500million Levelsoftwelvemonthsalesatwhichsalesmilestonepaymentswerereceived500million	500000000	USD
	regn	Levelsoftwelvemonthsalesatwhichsalesmilestonepaymentswerereceived600million Levelsoftwelvemonthsalesatwhichsalesmilestonepaymentswerereceived600million	600000000	USD
	regn	Levelsoftwelvemonthsalesatwhichsalesmilestonepaymentswerereceived700million Levelsoftwelvemonthsalesatwhichsalesmilestonepaymentswerereceived700million	700000000	USD
CY2014Q3	regn	Levelsoftwelvemonthsalesatwhichsalesmilestonepaymentswerereceived800million Levelsoftwelvemonthsalesatwhichsalesmilestonepaymentswerereceived800million	800000000	USD
CY2014Q3	regn	Levelsoftwelvemonthsalesatwhichsalesmilestonepaymentswerereceived900million Levelsoftwelvemonthsalesatwhichsalesmilestonepaymentswerereceived900million	900000000	USD
	regn	Numberofdevelopmentmilestonepaymentsthe Companyreceived NumberofdevelopmentmilestonepaymentstheCompanyreceived	3000000
	regn	Numberofsalesmilestonepaymentsthe Companyreceived NumberofsalesmilestonepaymentstheCompanyreceived	5
CY2014Q3	regn	Numberofsalesmilestonepaymentsthe Companyreceived NumberofsalesmilestonepaymentstheCompanyreceived	2
CY2015Q1	regn	Numberofsalesmilestonepaymentsthe Companyreceived NumberofsalesmilestonepaymentstheCompanyreceived	1
CY2014Q3	regn	Other Collaboration Revenue OtherCollaborationRevenue	135853000	USD
	regn	Other Collaboration Revenue OtherCollaborationRevenue	358460000	USD
CY2015Q3	regn	Other Collaboration Revenue OtherCollaborationRevenue	157596000	USD
	regn	Other Collaboration Revenue OtherCollaborationRevenue	415679000	USD
	regn	Period For Achieving Sales Target For Milestone Payment Rolling Basis PeriodForAchievingSalesTargetForMilestonePaymentRollingBasis	P12M
CY2015Q1	regn	Period For Achieving Sales Target For Milestone Payment Rolling Basis PeriodForAchievingSalesTargetForMilestonePaymentRollingBasis	P12M
CY2014Q4	regn	Reductioninaccountsreceivable Reductioninaccountsreceivable	41000000	USD
CY2014Q4	regn	Reductioninincometaxassetsnet Reductioninincometaxassetsnet	14200000	USD
	regn	Stockissuedduringperiodconversionofconvertiblenotes Stockissuedduringperiodconversionofconvertiblenotes	521876	shares
	regn	Stockissuedduringperiodconversionofconvertiblenotes Stockissuedduringperiodconversionofconvertiblenotes	1419287	shares
CY2014Q4	us-gaap	Accounts And Notes Receivable Net AccountsAndNotesReceivableNet	125483000	USD
CY2015Q3	us-gaap	Accounts And Notes Receivable Net AccountsAndNotesReceivableNet	151991000	USD
CY2014Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	483489000	USD
CY2015Q3	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	577428000	USD
CY2014Q4	us-gaap	Accounts Payable Trade Current AccountsPayableTradeCurrent	99508000	USD
CY2015Q3	us-gaap	Accounts Payable Trade Current AccountsPayableTradeCurrent	106917000	USD
CY2014Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	739379000	USD
CY2015Q3	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	1088207000	USD
CY2014Q4	us-gaap	Accounts Receivable Related Parties Current AccountsReceivableRelatedPartiesCurrent	111510000	USD
CY2015Q3	us-gaap	Accounts Receivable Related Parties Current AccountsReceivableRelatedPartiesCurrent	199117000	USD
CY2014Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	52251000	USD
CY2015Q3	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	7721000	USD
CY2014Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	2450782000	USD
CY2015Q3	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	2880109000	USD
	us-gaap	Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities	306229000	USD
	us-gaap	Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities	567895000	USD
CY2014Q4	us-gaap	Assets Assets	3837672000	USD
CY2015Q3	us-gaap	Assets Assets	5182915000	USD
CY2014Q4	us-gaap	Assets Current AssetsCurrent	2130938000	USD
CY2015Q3	us-gaap	Assets Current AssetsCurrent	2675640000	USD
CY2014Q4	us-gaap	Available For Sale Securities AvailableForSaleSecurities	711915000	USD
CY2015Q3	us-gaap	Available For Sale Securities AvailableForSaleSecurities	922381000	USD
CY2014Q4	us-gaap	Available For Sale Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	81989000	USD
CY2015Q3	us-gaap	Available For Sale Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	11622000	USD
CY2014Q4	us-gaap	Available For Sale Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	1551000	USD
CY2015Q3	us-gaap	Available For Sale Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	1087000	USD
CY2014Q4	us-gaap	Available For Sale Securities Amortized Cost AvailableForSaleSecuritiesAmortizedCost	631477000	USD
CY2015Q3	us-gaap	Available For Sale Securities Amortized Cost AvailableForSaleSecuritiesAmortizedCost	911846000	USD
CY2014Q4	us-gaap	Available For Sale Securities Continuous Unrealized Loss Position12 Months Or Longer Accumulated Loss AvailableForSaleSecuritiesContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss	0	USD
CY2015Q3	us-gaap	Available For Sale Securities Continuous Unrealized Loss Position12 Months Or Longer Accumulated Loss AvailableForSaleSecuritiesContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss	29000	USD
CY2014Q4	us-gaap	Available For Sale Securities Continuous Unrealized Loss Position Accumulated Loss AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLoss	1551000	USD
CY2015Q3	us-gaap	Available For Sale Securities Continuous Unrealized Loss Position Accumulated Loss AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLoss	1087000	USD
CY2014Q4	us-gaap	Available For Sale Securities Continuous Unrealized Loss Position Fair Value AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValue	426941000	USD
CY2015Q3	us-gaap	Available For Sale Securities Continuous Unrealized Loss Position Fair Value AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValue	426170000	USD
CY2014Q4	us-gaap	Available For Sale Securities Continuous Unrealized Loss Position Less Than12 Months Accumulated Loss AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss	1551000	USD
CY2015Q3	us-gaap	Available For Sale Securities Continuous Unrealized Loss Position Less Than12 Months Accumulated Loss AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss	1058000	USD
CY2014Q4	us-gaap	Available For Sale Securities Continuous Unrealized Loss Position Less Than Twelve Months Fair Value AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue	426941000	USD
CY2015Q3	us-gaap	Available For Sale Securities Continuous Unrealized Loss Position Less Than Twelve Months Fair Value AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue	395887000	USD
CY2014Q4	us-gaap	Available For Sale Securities Continuous Unrealized Loss Position Twelve Months Or Longer Fair Value AvailableForSaleSecuritiesContinuousUnrealizedLossPositionTwelveMonthsOrLongerFairValue	0	USD
CY2015Q3	us-gaap	Available For Sale Securities Continuous Unrealized Loss Position Twelve Months Or Longer Fair Value AvailableForSaleSecuritiesContinuousUnrealizedLossPositionTwelveMonthsOrLongerFairValue	30283000	USD
CY2014Q4	us-gaap	Available For Sale Securities Debt Maturities After Five Through Ten Years Fair Value AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue	1128000	USD
CY2015Q3	us-gaap	Available For Sale Securities Debt Maturities After Five Through Ten Years Fair Value AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue	0	USD
CY2014Q4	us-gaap	Available For Sale Securities Debt Maturities After One Through Five Years Fair Value AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue	360208000	USD
CY2015Q3	us-gaap	Available For Sale Securities Debt Maturities After One Through Five Years Fair Value AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue	653779000	USD
CY2014Q4	us-gaap	Available For Sale Securities Debt Maturities Within One Year Fair Value AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue	251761000	USD
CY2015Q3	us-gaap	Available For Sale Securities Debt Maturities Within One Year Fair Value AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue	241055000	USD
CY2014Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	613097000	USD
CY2015Q3	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	894834000	USD
CY2014Q3	us-gaap	Available For Sale Securities Income Tax Expense On Change In Unrealized Holding Gain Or Loss AvailableForSaleSecuritiesIncomeTaxExpenseOnChangeInUnrealizedHoldingGainOrLoss	-13500000.0	USD
	us-gaap	Available For Sale Securities Income Tax Expense On Change In Unrealized Holding Gain Or Loss AvailableForSaleSecuritiesIncomeTaxExpenseOnChangeInUnrealizedHoldingGainOrLoss	-14900000.0	USD
CY2015Q3	us-gaap	Available For Sale Securities Income Tax Expense On Change In Unrealized Holding Gain Or Loss AvailableForSaleSecuritiesIncomeTaxExpenseOnChangeInUnrealizedHoldingGainOrLoss	-6500000.0	USD
	us-gaap	Available For Sale Securities Income Tax Expense On Change In Unrealized Holding Gain Or Loss AvailableForSaleSecuritiesIncomeTaxExpenseOnChangeInUnrealizedHoldingGainOrLoss	-25373000	USD
CY2013Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	535608000	USD
CY2014Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	646554000	USD
CY2014Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	648719000	USD
CY2015Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	654587000	USD
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	110946000	USD
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	5868000	USD
CY2014Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	106007000	USD
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	276114000	USD
CY2015Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	198966000	USD
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	436532000	USD
CY2014Q4	us-gaap	Convertible Long Term Notes Payable ConvertibleLongTermNotesPayable	146773000	USD
CY2015Q3	us-gaap	Convertible Long Term Notes Payable ConvertibleLongTermNotesPayable	30723000	USD
CY2013Q4	us-gaap	Convertible Notes Payable Current ConvertibleNotesPayableCurrent	0	USD
CY2014Q3	us-gaap	Convertible Notes Payable Current ConvertibleNotesPayableCurrent	0	USD
CY2014Q4	us-gaap	Convertible Notes Payable Current ConvertibleNotesPayableCurrent	7500000	USD
CY2015Q3	us-gaap	Convertible Notes Payable Current ConvertibleNotesPayableCurrent	300000	USD
CY2014Q3	us-gaap	Cost Of Goods Sold CostOfGoodsSold	33655000	USD
	us-gaap	Cost Of Goods Sold CostOfGoodsSold	91073000	USD
CY2015Q3	us-gaap	Cost Of Goods Sold CostOfGoodsSold	67199000	USD
	us-gaap	Cost Of Goods Sold CostOfGoodsSold	170624000	USD
CY2014Q3	us-gaap	Costs And Expenses CostsAndExpenses	537324000	USD
	us-gaap	Costs And Expenses CostsAndExpenses	1409112000	USD
CY2014Q4	us-gaap	Costs And Expenses CostsAndExpenses	586526000	USD
CY2014	us-gaap	Costs And Expenses CostsAndExpenses	1995638000	USD
CY2015Q3	us-gaap	Costs And Expenses CostsAndExpenses	745000000	USD
	us-gaap	Costs And Expenses CostsAndExpenses	1984817000	USD
CY2015Q3	us-gaap	Debt Instrument Face Amount DebtInstrumentFaceAmount	33100000	USD
CY2011Q4	us-gaap	Debt Instrument Face Amount DebtInstrumentFaceAmount	400000000	USD
	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-43547000	USD
CY2014Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	58098000	USD
CY2015Q3	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	54148000	USD
CY2014Q4	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	72430000	USD
CY2015Q3	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	78942000	USD
CY2014Q4	us-gaap	Deferred Tax Assets Liabilities Net Current DeferredTaxAssetsLiabilitiesNetCurrent	46179000	USD
CY2015Q3	us-gaap	Deferred Tax Assets Liabilities Net Current DeferredTaxAssetsLiabilitiesNetCurrent	60521000	USD
CY2014Q4	us-gaap	Deferred Tax Assets Liabilities Net Noncurrent DeferredTaxAssetsLiabilitiesNetNoncurrent	269237000	USD
CY2015Q3	us-gaap	Deferred Tax Assets Liabilities Net Noncurrent DeferredTaxAssetsLiabilitiesNetNoncurrent	346243000	USD
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	38551000	USD
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	51999000	USD
CY2014Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.83
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	2.47
CY2014Q4	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.89
CY2014	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	3.36
CY2015Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	2.04
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	4.68
CY2014Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.73
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	2.19
CY2014Q4	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.78
CY2014	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	2.98
CY2015Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	1.82
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	4.18
CY2014Q3	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.541
	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.566
CY2015Q3	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.465
	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.518
	us-gaap	Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate	0.022
	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0
CY2014Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	92778000	USD
CY2015Q3	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	120933000	USD
	us-gaap	Excess Tax Benefit From Share Based Compensation Financing Activities ExcessTaxBenefitFromShareBasedCompensationFinancingActivities	334146000	USD
	us-gaap	Excess Tax Benefit From Share Based Compensation Financing Activities ExcessTaxBenefitFromShareBasedCompensationFinancingActivities	305551000	USD
CY2014Q3	us-gaap	Fair Value Assets Level2 To Level1 Transfers Amount FairValueAssetsLevel2ToLevel1TransfersAmount	0	USD
CY2015Q3	us-gaap	Fair Value Assets Level2 To Level1 Transfers Amount FairValueAssetsLevel2ToLevel1TransfersAmount	0	USD
CY2015Q1	us-gaap	Fair Value Assets Level2 To Level1 Transfers Amount FairValueAssetsLevel2ToLevel1TransfersAmount	91400000	USD
CY2014Q3	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	0	USD
	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-10787000	USD
CY2015Q3	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-21000	USD
	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-16927000	USD
CY2014Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	181823000	USD
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	571512000	USD
CY2014Q4	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	189723000	USD
CY2014	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	761235000	USD
CY2015Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	393289000	USD
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	997808000	USD
CY2014Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	98448000	USD
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	323481000	USD
CY2014Q4	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	99628000	USD
CY2014	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	423109000	USD
CY2015Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	182891000	USD
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	516746000	USD
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	76506000	USD
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	164652000	USD
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-53642000	USD
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	462943000	USD
	us-gaap	Increase Decrease In Deferred Income Taxes IncreaseDecreaseInDeferredIncomeTaxes	34161000	USD
	us-gaap	Increase Decrease In Deferred Income Taxes IncreaseDecreaseInDeferredIncomeTaxes	65975000	USD
	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	3466000	USD
	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	624063000	USD
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	50917000	USD
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	81459000	USD
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	28850000	USD
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	13223000	USD
CY2014Q3	us-gaap	Incremental Common Shares Attributable To Call Options And Warrants IncrementalCommonSharesAttributableToCallOptionsAndWarrants	2787000	shares
	us-gaap	Incremental Common Shares Attributable To Call Options And Warrants IncrementalCommonSharesAttributableToCallOptionsAndWarrants	2950000	shares
CY2015Q3	us-gaap	Incremental Common Shares Attributable To Call Options And Warrants IncrementalCommonSharesAttributableToCallOptionsAndWarrants	2175000	shares
	us-gaap	Incremental Common Shares Attributable To Call Options And Warrants IncrementalCommonSharesAttributableToCallOptionsAndWarrants	2395000	shares
CY2014Q3	us-gaap	Incremental Common Shares Attributable To Conversion Of Debt Securities IncrementalCommonSharesAttributableToConversionOfDebtSecurities	4033000	shares
CY2015Q3	us-gaap	Incremental Common Shares Attributable To Conversion Of Debt Securities IncrementalCommonSharesAttributableToConversionOfDebtSecurities	308000	shares
CY2014Q3	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	9377000	shares
	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	9515000	shares
CY2015Q3	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	9632000	shares
	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	9449000	shares
CY2014Q3	us-gaap	Interest Expense InterestExpense	9232000	USD
	us-gaap	Interest Expense InterestExpense	31022000	USD
CY2015Q3	us-gaap	Interest Expense InterestExpense	1715000	USD
	us-gaap	Interest Expense InterestExpense	10632000	USD
CY2014Q3	us-gaap	Interest On Convertible Debt Net Of Tax InterestOnConvertibleDebtNetOfTax	2803000	USD
CY2015Q3	us-gaap	Interest On Convertible Debt Net Of Tax InterestOnConvertibleDebtNetOfTax	145000	USD
CY2014Q4	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	10768000	USD
CY2015Q3	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	12513000	USD
CY2014Q4	us-gaap	Inventory Net InventoryNet	128861000	USD
CY2015Q3	us-gaap	Inventory Net InventoryNet	190668000	USD
CY2014Q4	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	10923000	USD
CY2015Q3	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	34983000	USD
CY2014Q3	us-gaap	Inventory Write Down InventoryWriteDown	1600000	USD
	us-gaap	Inventory Write Down InventoryWriteDown	3500000	USD
CY2014Q4	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	73519000	USD
CY2015Q3	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	110616000	USD
CY2015Q3	us-gaap	Inventory Write Down InventoryWriteDown	1800000	USD
	us-gaap	Inventory Write Down InventoryWriteDown	9900000	USD
CY2014Q4	us-gaap	Liabilities Liabilities	1287421000	USD
CY2015Q3	us-gaap	Liabilities Liabilities	1886048000	USD
CY2014Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	3837672000	USD
CY2015Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	5182915000	USD
CY2014Q4	us-gaap	Liabilities Current LiabilitiesCurrent	654660000	USD
CY2015Q3	us-gaap	Liabilities Current LiabilitiesCurrent	734990000	USD
CY2014Q3	us-gaap	Licenses Revenue LicensesRevenue	8166000	USD
	us-gaap	Licenses Revenue LicensesRevenue	23496000	USD
CY2015Q3	us-gaap	Licenses Revenue LicensesRevenue	17529000	USD
	us-gaap	Licenses Revenue LicensesRevenue	56817000	USD
CY2014Q4	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	251761000	USD
CY2015Q3	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	241055000	USD
CY2014Q4	us-gaap	Marketable Securities Noncurrent MarketableSecuritiesNoncurrent	460154000	USD
CY2015Q3	us-gaap	Marketable Securities Noncurrent MarketableSecuritiesNoncurrent	681326000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	34108000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-258788000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-477422000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-784301000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	554260000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	1048957000	USD
CY2014Q3	us-gaap	Net Income Loss NetIncomeLoss	83375000	USD
	us-gaap	Net Income Loss NetIncomeLoss	248031000	USD
CY2014Q4	us-gaap	Net Income Loss NetIncomeLoss	90095000	USD
CY2014	us-gaap	Net Income Loss NetIncomeLoss	338126000	USD
CY2015Q3	us-gaap	Net Income Loss NetIncomeLoss	210398000	USD
	us-gaap	Net Income Loss NetIncomeLoss	481062000	USD
CY2014Q3	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	86178000	USD
CY2015Q3	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	210543000	USD
CY2014Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-6641000	USD
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-36604000	USD
CY2015Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	867000	USD
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-23026000	USD
CY2014Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	188464000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	608116000	USD
CY2014Q4	us-gaap	Operating Income Loss OperatingIncomeLoss	215803000	USD
CY2014	us-gaap	Operating Income Loss OperatingIncomeLoss	823919000	USD
CY2015Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	392422000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	1020834000	USD
CY2014Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	116563000	USD
CY2015Q3	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	126068000	USD
CY2014Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	3034000	USD
CY2015Q3	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	4583000	USD
CY2014Q3	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	22632000	USD
	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	28083000	USD
CY2015Q3	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-11432000	USD
	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-44530000	USD
CY2014Q4	us-gaap	Other Inventory Net Of Reserves OtherInventoryNetOfReserves	33651000	USD
CY2015Q3	us-gaap	Other Inventory Net Of Reserves OtherInventoryNetOfReserves	32556000	USD
CY2014Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	97146000	USD
CY2015Q3	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	2506000	USD
CY2014Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	39801000	USD
CY2015Q3	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	77910000	USD
	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	-28473000	USD
	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	-33197000	USD
CY2014Q3	us-gaap	Other Nonoperating Income OtherNonoperatingIncome	2591000	USD
	us-gaap	Other Nonoperating Income OtherNonoperatingIncome	5205000	USD
CY2015Q3	us-gaap	Other Nonoperating Income OtherNonoperatingIncome	2603000	USD
	us-gaap	Other Nonoperating Income OtherNonoperatingIncome	4533000	USD
	us-gaap	Payments For Repurchase Of Warrants PaymentsForRepurchaseOfWarrants	143041000	USD
	us-gaap	Payments For Repurchase Of Warrants PaymentsForRepurchaseOfWarrants	523487000	USD
	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	175866000	USD
	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	71673000	USD
	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	478436000	USD
	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	550142000	USD
	us-gaap	Payments To Acquire Productive Assets PaymentsToAcquireProductiveAssets	215464000	USD
	us-gaap	Payments To Acquire Productive Assets PaymentsToAcquireProductiveAssets	500154000	USD
CY2014Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.01
CY2015Q3	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.01
CY2014Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	30000000	shares
CY2015Q3	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	30000000	shares
CY2014Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2015Q3	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2014Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2015Q3	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2014Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2015Q3	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2014Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	79046000	USD
CY2015Q3	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	89494000	USD
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	80804000	USD
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	150423000	USD
	us-gaap	Proceeds From Repayments Of Long Term Debt And Capital Securities ProceedsFromRepaymentsOfLongTermDebtAndCapitalSecurities	-810000	USD
	us-gaap	Proceeds From Repayments Of Long Term Debt And Capital Securities ProceedsFromRepaymentsOfLongTermDebtAndCapitalSecurities	26405000	USD
	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	216478000	USD
	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	265995000	USD
CY2014Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	974309000	USD
CY2015Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1475123000	USD
	us-gaap	Repayments Of Convertible Debt RepaymentsOfConvertibleDebt	61125000	USD
	us-gaap	Repayments Of Convertible Debt RepaymentsOfConvertibleDebt	146007000	USD
CY2014Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	337728000	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	919608000	USD
CY2015Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	425924000	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1159367000	USD
CY2014Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	216644000	USD
CY2015Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	697706000	USD
CY2014Q3	us-gaap	Revenue From Related Parties RevenueFromRelatedParties	132925000	USD
	us-gaap	Revenue From Related Parties RevenueFromRelatedParties	406028000	USD
CY2015Q3	us-gaap	Revenue From Related Parties RevenueFromRelatedParties	224735000	USD
	us-gaap	Revenue From Related Parties RevenueFromRelatedParties	593201000	USD
CY2014Q3	us-gaap	Revenues Revenues	725788000	USD
	us-gaap	Revenues Revenues	2017228000	USD
CY2015Q3	us-gaap	Revenues Revenues	1137422000	USD
	us-gaap	Revenues Revenues	3005651000	USD
CY2014Q3	us-gaap	Sales Revenue Goods Net SalesRevenueGoodsNet	448844000	USD
	us-gaap	Sales Revenue Goods Net SalesRevenueGoodsNet	1229244000	USD
CY2015Q3	us-gaap	Sales Revenue Goods Net SalesRevenueGoodsNet	737562000	USD
	us-gaap	Sales Revenue Goods Net SalesRevenueGoodsNet	1939954000	USD
CY2014Q3	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	144003000	USD
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	343960000	USD
CY2014Q4	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	175307000	USD
CY2014	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	519267000	USD
CY2015Q3	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	209993000	USD
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	543572000	USD
CY2014Q3	us-gaap	Share Based Compensation ShareBasedCompensation	68100000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	208732000	USD
CY2015Q3	us-gaap	Share Based Compensation ShareBasedCompensation	102600000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	300657000	USD
CY2014Q4	us-gaap	Stockholders Equity StockholdersEquity	2550251000	USD
CY2015Q3	us-gaap	Stockholders Equity StockholdersEquity	3296867000	USD
CY2014Q4	us-gaap	Treasury Stock Shares TreasuryStockShares	2017732	shares
CY2015Q3	us-gaap	Treasury Stock Shares TreasuryStockShares	3437000	shares
CY2014Q4	us-gaap	Treasury Stock Value TreasuryStockValue	169530000	USD
CY2015Q3	us-gaap	Treasury Stock Value TreasuryStockValue	288777000	USD
CY2013Q4	us-gaap	Valuation Allowances And Reserves Balance ValuationAllowancesAndReservesBalance	24601000	USD
CY2014Q3	us-gaap	Valuation Allowances And Reserves Balance ValuationAllowancesAndReservesBalance	22795000	USD
CY2014Q4	us-gaap	Valuation Allowances And Reserves Balance ValuationAllowancesAndReservesBalance	24781000	USD
CY2015Q3	us-gaap	Valuation Allowances And Reserves Balance ValuationAllowancesAndReservesBalance	45074000	USD
	us-gaap	Valuation Allowances And Reserves Charged To Other Accounts ValuationAllowancesAndReservesChargedToOtherAccounts	78156000	USD
	us-gaap	Valuation Allowances And Reserves Charged To Other Accounts ValuationAllowancesAndReservesChargedToOtherAccounts	135363000	USD
	us-gaap	Valuation Allowances And Reserves Deductions ValuationAllowancesAndReservesDeductions	79962000	USD
	us-gaap	Valuation Allowances And Reserves Deductions ValuationAllowancesAndReservesDeductions	115070000	USD
CY2014Q3	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	16627000	shares
	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	12878000	shares
CY2015Q3	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	12596000	shares
	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	12319000	shares
CY2014Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	117423000	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	113203000	shares
CY2015Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	115944000	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	115144000	shares
CY2014Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	100796000	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	100325000	shares
CY2015Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	103348000	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	102825000	shares
	us-gaap	Description Of New Accounting Pronouncements Not Yet Adopted DescriptionOfNewAccountingPronouncementsNotYetAdopted	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Recently Issued Accounting Standards </font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;text-indent:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In May 2014, the FASB issued a new standard related to revenue recognition, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Revenue from Contracts with Customers</font><font style="font-family:inherit;font-size:10pt;">, which will replace existing revenue recognition guidance. The new standard requires an entity to recognize the amount of revenue to which it expects to be entitled for the transfer of promised goods or services to customers. To achieve that core principle, an entity must identify the contract(s) with a customer, identify the performance obligations in the contract, determine the transaction price, allocate the transaction price to the performance obligations in the contract, and recognize revenue when (or as) the entity satisfies the performance obligation. In July 2015, the FASB decided to delay the effective date of the new standard by one year; as a result, the new standard will be effective for annual and interim reporting periods beginning after December 15, 2017. Early adoption will be permitted, but no earlier than 2017 for calendar year-end entities. The standard allows for two transition methods - retrospectively to each prior reporting period presented or retrospectively with the cumulative effect of initially applying the standard recognized at the date of initial adoption. The Company has not yet determined its method of transition and is evaluating the impact that this guidance will have on the Company's financial statements.</font></div></div>
	us-gaap	Revenue Recognition Revenue Reductions RevenueRecognitionRevenueReductions	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;text-indent:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Revenue from product sales is recorded net of applicable provisions for rebates and chargebacks under governmental programs, distribution-related fees, and other sales-related deductions. </font></div></div>

Files In Submission

Name	View Source	Status
0001532176-15-000037-index-headers.html	Edgar Link	pending
0001532176-15-000037-index.html	Edgar Link	pending
0001532176-15-000037.txt	Edgar Link	pending
0001532176-15-000037-xbrl.zip	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
regn-093015x10q.htm	Edgar Link	pending
regn-20150930.xml	Edgar Link	completed
regn-20150930.xsd	Edgar Link	pending
regn-20150930_cal.xml	Edgar Link	unprocessable
regn-20150930_def.xml	Edgar Link	unprocessable
regn-20150930_lab.xml	Edgar Link	unprocessable
regn-20150930_pre.xml	Edgar Link	unprocessable
regn-ex_101x09302015x10q.htm	Edgar Link	pending
regn-ex_102x09302015x10q.htm	Edgar Link	pending
regn-ex_103x09302015x10q.htm	Edgar Link	pending
regn-ex_104x09302015x10q.htm	Edgar Link	pending
regn-ex_105x09302015x10q.htm	Edgar Link	pending
regn-ex_106x09302015x10q.htm	Edgar Link	pending
regn-ex_107x09302015x10q.htm	Edgar Link	pending
regn-ex_311x09302015x10q.htm	Edgar Link	pending
regn-ex_312x09302015x10q.htm	Edgar Link	pending
regn-ex_32x09302015x10q.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$REGN
Regeneron Pharmaceuticals Inc Stock $regn

2015 Q3 Form 10-Q Financial Statement

#000153217615000037 Filed on November 04, 2015

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$REGN Regeneron Pharmaceuticals Inc Stock $regn

2015 Q3 Form 10-Q Financial Statement

#000153217615000037 Filed on November 04, 2015

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$REGN
Regeneron Pharmaceuticals Inc Stock $regn